Results 21 to 30 of about 1,727,618 (310)

HIV-1 Env Does Not Enable the Development of Protective Broadly Neutralizing Antibodies in an Experimental Autoimmune Encephalomyelitis Mouse Model

Frontiers in Immunology, 2021
Recent studies showed that immunological tolerance may restrict the development of Env-specific autoreactive broadly neutralizing antibodies. This evidence is consistent with the finding that Env immunization of a systemic lupus erythematosus (SLE ...
Gabriel Siracusano, Annamaria Finardi, Claudia Pastori, Vittorio Martinelli, Roberto Furlan, Lucia Lopalco   +5 more
doaj   +1 more source

Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals

Nature Network Boston, 2022
In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern. Modified vaccinia Ankara—Bavarian Nordic (MVA-BN, also known as Imvamune, JYNNEOS or Imvanex) is a third-generation smallpox vaccine that ...
Luca M. Zaeck, M. Lamers, B. Verstrepen, T. Bestebroer, M. V. van Royen, H. Götz, M. Shamier, L. V. van Leeuwen, K. Schmitz, Kimberley Alblas, Suzanne van Efferen, S. Bogers, S. Scherbeijn, G. Rimmelzwaan, E. V. van Gorp, M. Koopmans, B. Haagmans, C. Geurtsvankessel, R. D. de Vries   +18 more
semanticscholar   +1 more source

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

bioRxiv, 2021
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative infection of a global pandemic that has led to more than 2 million deaths worldwide.
Kai Wu, Anne P. Werner, Juan I. Moliva, M. Koch, A. Choi, Guillaume B. E. Stewart-Jones, H. Bennett, Seyhan Boyoglu-Barnum, W. Shi, B. Graham, A. Carfi, Kizzmekia S. Corbett, R. Seder, D. Edwards   +13 more
semanticscholar   +1 more source

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Science, 2021
Boosterism could save lives Postinfection immune protection against severe acute respiratory syndrome coronavirus 2 reinfection is not fully understood.
L. Stamatatos, Julie L. Czartoski, Yu-Hsin Wan, Leah J. Homad, Vanessa Rubin, Hayley Glantz, M. Neradilek, Emilie Seydoux, Madeleine F. Jennewein, Anna J. MacCamy, Junli Feng, G. Mize, S. D. De Rosa, A. Finzi, Maria P. Lemos, Kristen W. Cohen, Z. Moodie, M. McElrath, A. McGuire   +18 more
semanticscholar   +1 more source

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. [PDF]

PLoS Pathogens, 2017
Human cytomegalovirus (HCMV) is an important, ubiquitous pathogen that causes severe clinical disease in immunocompromised individuals, such as organ transplant recipients and infants infected in utero.
Anna Bootz, Astrid Karbach, Johannes Spindler, Barbara Kropff, Nina Reuter, Heinrich Sticht, Thomas H Winkler, William J Britt, Michael Mach   +8 more
doaj   +1 more source

Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19

Human Vaccines & Immunotherapeutics, 2023
This post-hoc analysis compared the receptor-binding domain (RBD)-specific and pseudovirus neutralizing antibodies against the wild-type SARS-CoV-2 strain elicited by one or two doses (56-d interval) of Ad5-nCoV vaccine regimen (NCT04341389 and ...
Jia-Lu Feng, Wen-Juan Wang, Peng-Fei Jin, Hui Zheng, Lai-Run Jin, Xin Xia, Xiao-Yin Zhang, Zhuo-Pei Li, Jing-Xin Li, Feng-Cai Zhu   +9 more
doaj   +1 more source

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Science, 2020
SARS-CoV-2 antibodies persist As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al.
A. Wajnberg, F. Amanat, A. Firpo, D. Altman, M. Bailey, M. Mansour, Meagan McMahon, Philip Meade, D. R. Mendu, K. Muellers, D. Stadlbauer, K. Stone, Shirin Strohmeier, V. Simon, J. Aberg, D. Reich, F. Krammer, C. Cordon-Cardo   +17 more
semanticscholar   +1 more source

Neutralizing Antibody Therapeutics for COVID-19 [PDF]

Viruses, 2021
The emergence of SARS-CoV-2 and subsequent COVID-19 pandemic has resulted in a significant global public health burden, leading to an urgent need for effective therapeutic strategies. In this article, we review the role of SARS-CoV-2 neutralizing antibodies (nAbs) in the clinical management of COVID-19 and provide an overview of recent randomized ...
Hurt, AC, Wheatley, AK
openaire   +5 more sources

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Science, 2020
An antibody defense against COVID-19 One of the responses of the immune system to invading viruses is the production of antibodies. Some of these are neutralizing, meaning that they prevent the virus from being infectious, and can thus be used to treat ...
Yan Wu, Feiran Wang, Chenguang Shen, Weiyu Peng, Delin Li, Cheng Zhao, Z. Li, Shihua Li, Y. Bi, Yang Yang, Y. Gong, Haixia Xiao, Z. Fan, Shuguang Tan, Guizhen Wu, W. Tan, Xuancheng Lu, Changfa Fan, Qihui Wang, Yingxia Liu, Chen Zhang, J. Qi, G. Gao, F. Gao, Lei Liu   +24 more
semanticscholar   +1 more source

Identification of a conserved neutralizing epitope in Seneca Valley virus VP2 protein: new insight for epitope vaccine designment

Virology Journal, 2022
Background Seneca Valley virus (SVV) is a picornavirus that causes vesicular disease in swine. Clinical characteristics of the disease are similar to common viral diseases such as foot-and-mouth disease virus, porcine vesicular disease virus, and ...
Wei Wen, Xinghua Chen, Qiang Lv, Huanchun Chen, Ping Qian, Xiangmin Li   +5 more
doaj   +1 more source